Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Daclatasvir plus sofosbuvir for HCV infection.

Sulkowski MS, Jacobson IM, Nelson DR.

N Engl J Med. 2014 Apr 17;370(16):1560-1. doi: 10.1056/NEJMc1401726. No abstract available.

2.

Daclatasvir plus sofosbuvir for HCV infection.

Dhaliwal HS, Nampoothiri RV.

N Engl J Med. 2014 Apr 17;370(16):1560. doi: 10.1056/NEJMc1401726#SA1. No abstract available.

PMID:
24738675
3.

Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

Asselah T.

J Hepatol. 2014 Aug;61(2):435-8. doi: 10.1016/j.jhep.2014.04.042. No abstract available.

4.

Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3.

Bari K, Sharma P.

Gastroenterology. 2014 Aug;147(2):534-6. doi: 10.1053/j.gastro.2014.06.016. No abstract available.

PMID:
24953626
5.

[Begin of a new era in treating hepatitis C in Patients on the waiting list and after liver transplantation].

Beckebaum SK, Schmidt HH.

Z Gastroenterol. 2014 Jul;52(7):746-8. doi: 10.1055/s-0034-1366287. German. No abstract available.

PMID:
25026012
6.

[The beginning of the end for interferon therapy? - novel interferon-free treatment options for hepatitis C].

Zimmermann HW, Tacke F.

Z Gastroenterol. 2014 May;52(5):450-2. doi: 10.1055/s-0034-1366260. German. No abstract available.

PMID:
24824911
7.

HCV treatment--no more room for interferonologists?

Drenth JP.

N Engl J Med. 2013 May 16;368(20):1931-2. doi: 10.1056/NEJMe1303818. No abstract available.

PMID:
23607592
8.

Sofosbuvir-based antiviral therapy for treatment naïve hepatitis C genotypes 1, 2, and 3.

Sharma P.

Gastroenterology. 2013 Jul;145(1):245-7. doi: 10.1053/j.gastro.2013.05.030. No abstract available.

PMID:
23721818
9.

Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.

Messori A, Maratea D, Fadda V, Trippoli S.

Aliment Pharmacol Ther. 2014 Jul;40(2):217-8. doi: 10.1111/apt.12823. No abstract available.

10.

Sofosbuvir-based interferon-free therapy for patients with HCV infection.

Asselah T.

J Hepatol. 2013 Dec;59(6):1342-5. doi: 10.1016/j.jhep.2013.07.023. No abstract available.

11.

Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients.

Vukotic R, Morelli MC, Pinna AD, Margotti M, Foschi FG, Loggi E, Bernardi M, Andreone P.

Aliment Pharmacol Ther. 2014 Aug;40(4):405. doi: 10.1111/apt.12853. No abstract available.

12.

Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.

Aghemo A, De Francesco R.

Gut. 2015 Jun;64(6):860-2. doi: 10.1136/gutjnl-2014-307958. No abstract available.

PMID:
25193803
13.

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M.

Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004.

PMID:
24997638
14.

Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.

Smith MA, Regal RE, Mohammad RA.

Ann Pharmacother. 2016 Jan;50(1):39-46. doi: 10.1177/1060028015610342. Review.

PMID:
26486762
15.

Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.

Barreiro P, Vispo E, Poveda E, Fernández-Montero JV, Soriano V.

Clin Infect Dis. 2013 Feb;56(4):560-6. doi: 10.1093/cid/cis915.

16.

[Sofosbuvir: alternative in hepatitis C infection?].

Blum HE.

Dtsch Med Wochenschr. 2013 Aug;138(33):1646-7. doi: 10.1055/s-0032-1329055. German. No abstract available.

PMID:
23913349
17.

Sofosbuvir for previously untreated chronic hepatitis C infection.

Hsu CS.

N Engl J Med. 2013 Aug 15;369(7):678. doi: 10.1056/NEJMc1307641#SA1. No abstract available.

PMID:
23944317
18.

Sofosbuvir for previously untreated chronic hepatitis C infection.

Lawitz E, Gane EJ.

N Engl J Med. 2013 Aug 15;369(7):678-9. doi: 10.1056/NEJMc1307641. No abstract available.

19.

No compelling reason to adopt new antivirals whenever it is reasonable to wait.

[No authors listed]

Prescrire Int. 2015 Jan;24(156):8. No abstract available.

PMID:
25729821
20.

[New hepatitis C treatments: pharmacological considerations and potential for drug interactions].

Chtioui H, Buclin T, Moradpour D.

Rev Med Suisse. 2014 Sep 3;10(440):1600-4, 1606. French.

PMID:
25276998
Items per page

Supplemental Content

Support Center